MaxCyte, Inc. Grant of Options (0898S)
July 12 2022 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0898S
MaxCyte, Inc.
12 July 2022
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, Maryland - 12 July 2022: MaxCyte Inc., (NASDAQ:
MXCT; LSE: MXCT), the global clinical-stage cell-based therapies
and life sciences company, announces that on 29 June 2022, a total
of 188,300 options of common stock in the Company ("Common Stock")
were granted to PDMRs who are non-executive directors of the
Company. These annual option grants were made pursuant to the
Company's Equity Grant Policy for non-executive directors ("Option
Grants"). Details of the Option Grants are given below:
Option Grants to PDMRs
Al-Wakeel, Yasir 26,900
--------
Brooke, Will 26,900
--------
Douglas, Richard 26,900
--------
Erck, Stanley 26,900
--------
Hemrajani, Rekha 26,900
--------
Johnston, John 26,900
--------
Mandell, Art 26,900
--------
Total 188,300
--------
Option Grants for non-executive directors fully vest at the end
of twelve (12) months after date of grant. (1 year cliff until
fully vested).
The Options Grants have an exercise period of 10 years from date
of grant, at which time they will expire, and have an exercise
price equal to the closing price of MaxCyte's stock on 29 June
2022, of 410 pence.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name a) Yasir Al-Wakeel
b) Will Brooke
c) Richard Douglas
d) Stanley Erck
e) Rekha Hemrajani
f) John Johnston
g) Art Mandell
--------------------------------- ----------------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status a) Non-Executive Director
b) Non-Executive Director
c) Non-Executive Chairman
d) Non-Executive Director
e) Non-Executive Director
f) Non-Executive Director
g) Non-Executive Director
--------------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- ----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name MaxCyte Inc.
--------------------------------- ----------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------------- ----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Common Stock of $0.01 each
financial instrument,
type of instrument
Identification code US57777K1060
b) Nature of the transaction Grant of options of common stock
--------------------------------- ----------------------------------------
c) Price(s) and volume(s)
----------------------- ------------
Exercise Price(s) Volume(s)
----------------------- ------------
a) GBP4.10 26,900
-------------------------------------------------------------- ------------
b) GBP4.10 26,900
-------------------------------------------------------------- ------------
c) GBP4.10 26,900
-------------------------------------------------------------- ------------
d) GBP4.10 26,900
-------------------------------------------------------------- ------------
e) GBP4.10 26,900
-------------------------------------------------------------- ------------
f) GBP4.10 26,900
-------------------------------------------------------------- ------------
g) GBP4.10 26,900
-------------------------------------------------------------- ------------
d) Aggregated information
- Aggregated volume 188,300
- Price GBP4.10
e) Date of the transaction 29 June 2022
--------------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
--------------------------------- ----------------------------------------
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHRBMLTMTMBBBT
(END) Dow Jones Newswires
July 12, 2022 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024